All In Biotech

Drug Trial Radar · NCT05307705

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

May 11, 2022

Primary completion

Apr 2, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.

Conditions

  • Breast Cancer

Interventions

  • LOXO-783Drug

    Oral

  • FulvestrantDrug

    Intramuscular

  • ImlunestrantDrug

    Oral

  • AbemaciclibDrug

    Oral

  • Anastrozole, Exemestane, or LetrozoleDrug

    Oral

  • PaclitaxelDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)Time frame: During the first 28-day cycle of LOXO-783 treatment
  2. Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicitiesTime frame: During the first 28-day cycle of LOXO-783 treatment

Locations

50 sites in 12 countries. Site status is shown where the registry gives one.

  • Mayo Clinic of Scottsdale

    Scottsdale, Arizona

  • UCLA Medical Center

    Los Angeles, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Stanford University Hospital

    Stanford, California

  • Mayo Clinic

    Jacksonville, Florida

  • Winship Cancer Center Emory University

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University Medical School

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Wilmot Cancer Institute

    Rochester, New York

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas

  • Cancer Research SA

    Adelaide, Australia

  • Peter Maccallum Cancer Institute Erb

    East Melbourne, Australia

  • St Vincent's Hospital

    Sydney, Australia

  • Institut Jules Bordet

    Anderlecht, Belgium

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Princess Margaret Hospital (Hong Kong)

    Toronto, Canada

  • BC Cancer Vancouver

    Vancouver, Canada

  • Beijing Cancer hospital

    Beijing, China

  • The Third Hospital of Nanchang

    Nanchang, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Centre Leon Berard

    Lyon, France

  • Institut Curie

    Paris, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, France

  • ICANS_Institut de Cancerologie Strasbourg Europe

    Strasbourg, France

  • Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • National Cancer Center Hospital

    Chūōku, Japan

  • The Cancer Institute Hospital of JFCR

    Kōtō City, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Aichi Cancer Center Hospital

    Nagoya, Japan

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Samsung Medical Center

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.